Literature DB >> 21489899

Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades.

Oddvar M Sandvik1, Kjetil Søreide, Jan Terje Kvaløy, Einar Gudlaugsson, Jon Arne Søreide.   

Abstract

BACKGROUND: Epidemiology of gastrointestinal stromal tumour (GIST) is sparsely described. We report a population-based consecutive case series of GIST over three decades from south-western Norway.
METHODS: All mesenchymal tumours registered at Stavanger University Hospital between 1980 and 2009 were reviewed and those of the gastrointestinal tract were reclassified with regard to histomorphology and/or immunohistochemistry profiles consistent with GIST. Reported are patients' characteristics and GIST incidence and prevalence estimated using population statistics.
RESULTS: Fifty-two cases were identified; 62% of the patients were women. Median age at diagnosis was 67 years. Fifty-eight percent of the tumours were located in the stomach, 38% in the small bowel and one each in colon and rectum. One third were considered to be high risk according to the NIH consensus criteria. The crude incidence rate of GIST was 1.8 per million in the study population per year in the 5-year period 1980-1984, and increased to around 6 in the following years with a peak at 12.5 per million in 2000-2004. The over all crude incidence rate for 1980-2009 was 6.5 per million (95% CI 4.8-8.3 per mill.). Standardized age- and gender adjusted incidence for Norway was 7.4 per million (95% CI 5.4-9.4). The number of patients alive with GIST increased over the study period, with a peak in 2000-2004 at 92.1 per million (95% CI 60.7-134.0 per mill.). One in five had an additional gastrointestinal cancer, located in the colon (n=6), rectum (n=2), stomach (n=3) or, pancreas (n=1).
CONCLUSION: Incidence of GIST in the south-western part of Norway is relatively stable and towards the lower end of the range reported in the worldwide literature. An increasing prevalence likely reflects therapy effects. Synchronous gastrointestinal cancers are relatively common in patients with GIST.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21489899     DOI: 10.1016/j.canep.2011.03.002

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  23 in total

Review 1.  Incidental Gastrointestinal Stromal Tumors (GISTs) and Bariatric Surgery: A Review.

Authors:  J A Fernández; M D Frutos; J J Ruiz-Manzanera
Journal:  Obes Surg       Date:  2020-07-24       Impact factor: 4.129

2.  Long-term and surgical outcomes of laparoscopic surgery for gastric gastrointestinal stromal tumors.

Authors:  Michitaka Honda; Naoki Hiki; Souya Nunobe; Manabu Ohashi; Takashi Kiyokawa; Takeshi Sano; Toshiharu Yamaguchi
Journal:  Surg Endosc       Date:  2014-02-25       Impact factor: 4.584

3.  HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach.

Authors:  Wen-Yi Zhao; Chun Zhuang; Jia Xu; Ming Wang; Zi-Zhen Zhang; Lin Tu; Chao-Jie Wang; Tian-Long Ling; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  Gastrointestinal Stromal Tumors After Laparoscopic Gastric Bypass for Morbid Obesity: a Diagnostic and Therapeutic Challenge.

Authors:  J A Fernández; M D Frutos; J J Ruiz-Manzanera; A Navarro; G Torres; T Soria
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

5.  Surgery for gastrointestinal stromal tumors (GISTs) of the stomach and small bowel: short- and long-term outcomes over three decades.

Authors:  Oddvar M Sandvik; Kjetil Søreide; Einar Gudlaugsson; Jon Arne Søreide
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

6.  Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy.

Authors:  Wen-Yi Zhao; Chun Zhuang; Jia Xu; Ming Wang; Zi-Zhen Zhang; Lin Tu; Chao-Jie Wang; Tian-Long Ling; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

7.  Prognostic value of Ki67 index in gastrointestinal stromal tumors.

Authors:  Wen-Yi Zhao; Jia Xu; Ming Wang; Zi-Zhen Zhang; Lin Tu; Chao-Jie Wang; Tian-Long Lin; Yan-Yin Shen; Qiang Liu; Hui Cao
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Gastrointestinal stromal tumor.

Authors:  Xiaohui Zhao; Changjun Yue
Journal:  J Gastrointest Oncol       Date:  2012-09

9.  Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Authors:  Kjetil Søreide; Oddvar M Sandvik; Jon Arne Søreide; Einar Gudlaugsson; Kjersti Mangseth; Hans Kristian Haugland
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

10.  Characterization of malignant gastrointestinal stromal tumors-a single center experience.

Authors:  Matteo Mandrioli; Laura Mastrangelo; Michele Masetti; Nicola Zanini; Stefania Lega; Margherita Nannini; Elisa Gruppioni; Annalisa Altimari; Angelo Paolo Dei Tos; Carlo Fabbri; Elio Jovine
Journal:  J Gastrointest Oncol       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.